Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer

This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab in combination with standard chemotherapy (cisplatin or carboplatin + etoposide) in the approved indication, which will be carried out in Greece. In this study data will be collected prospectively based on real-world clinical practice. A prospective cohort of atients from centers of the Hellenic Cooperative Oncology Group (HeCOG) will be included. The study will be conducted in hospitals and by physicians specialized in lung cancer from different geographical areas of Greece.

Inclusion Criteria:Male or female patients, regardless of race (residents in Greece), no younger than 18 years old at the initiation of treatment.Patients with histologically or cytologically confirmed diagnosis of extensive Small Cell Lung Cancer (SCLC)Patients who have not received prior systemic treatment for SCLC (chemotherapy or immunotherapy)Patients for whom the decision to administer treatment with Durvalumab+chemotherapy has already been taken before their inclusion in the study and is clearly separated from the decision of the physician for the patient's participation in the current study.Patients who have provided informed signed consent to participate in the study and to collect and analyze medical data related to the objectives of this study.Exclusion Criteria:Patients with current diagnosis of primary cancer other than SCLC who require systemic or other treatment.Patients who have previously received chemotherapy or immunotherapy for SCLCPatients who are currently receiving or are expected to receive treatment with an investigational drug/medical device/intervention or who have received an investigational medicinal product within 1 month or 5 years half-life of the research agent (whichever is longer) before their initiation in this study.